L

Liaoning Cheng Da Co Ltd
SSE:600739

Watchlist Manager
Liaoning Cheng Da Co Ltd
SSE:600739
Watchlist
Price: 9.59 CNY -0.72% Market Closed
Market Cap: 14.7B CNY
Have any thoughts about
Liaoning Cheng Da Co Ltd?
Write Note

Liaoning Cheng Da Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Liaoning Cheng Da Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
L
Liaoning Cheng Da Co Ltd
SSE:600739
Cash & Cash Equivalents
ÂĄ5.2B
CAGR 3-Years
42%
CAGR 5-Years
24%
CAGR 10-Years
21%
X
Xinhua Winshare Publishing and Media Co Ltd
SSE:601811
Cash & Cash Equivalents
ÂĄ8.2B
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
N/A
A
Anhui Xinhua Media Co Ltd
SSE:601801
Cash & Cash Equivalents
ÂĄ11.9B
CAGR 3-Years
21%
CAGR 5-Years
13%
CAGR 10-Years
21%
S
Sinomach Automobile Co Ltd
SSE:600335
Cash & Cash Equivalents
ÂĄ2.6B
CAGR 3-Years
-14%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
Zhejiang Orient Financial Holdings Group Co Ltd
SSE:600120
Cash & Cash Equivalents
ÂĄ4.9B
CAGR 3-Years
-6%
CAGR 5-Years
14%
CAGR 10-Years
17%
Wuchan Zhongda Group Co Ltd
SSE:600704
Cash & Cash Equivalents
ÂĄ14.1B
CAGR 3-Years
-13%
CAGR 5-Years
1%
CAGR 10-Years
14%
No Stocks Found

Liaoning Cheng Da Co Ltd
Glance View

Market Cap
14.6B CNY
Industry
Distributors

Liaoning Cheng Da Co Ltd stands as a significant player in the landscape of Chinese conglomerates, weaving a diverse portfolio that strategically aligns with the economic growth patterns of the region. Founded in the bustling province of Liaoning, the company epitomizes a model of diversified investment, underpinning its operations with a well-considered spread across various sectors. Initially, it carved a niche in the trading business, leveraging the abundant natural resources and industrial outputs of its home province to build a steady stream of revenue. This foundation allowed Cheng Da to expand into pharmaceuticals, real estate, and financial investments, each segment contributing distinctively to the company’s overall robustness. Cheng Da’s pharmaceutical business has emerged as a cornerstone, thriving amidst the rising demand for healthcare products in China. This arm of the company is particularly adept in leveraging advanced research methodologies combined with traditional Chinese medicine, thus creating a distinctive edge in both domestic and international markets. Meanwhile, its real estate ventures capably ride the wave of urbanization in China, focusing on premium residential and commercial properties, enhancing the urban landscape while adding to its financial metrics. By sitting at the crossroads of critical sectoral developments and maintaining a keen eye on expansive opportunities, Liaoning Cheng Da Co Ltd astutely navigates the intricate dance of market dynamics, thus cementing its place as a formidable entity in the economic engine of China.

Intrinsic Value
14.52 CNY
Undervaluation 34%
Intrinsic Value
Price
L

See Also

What is Liaoning Cheng Da Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
5.2B CNY

Based on the financial report for Sep 30, 2024, Liaoning Cheng Da Co Ltd's Cash & Cash Equivalents amounts to 5.2B CNY.

What is Liaoning Cheng Da Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
21%

Over the last year, the Cash & Cash Equivalents growth was 11%. The average annual Cash & Cash Equivalents growth rates for Liaoning Cheng Da Co Ltd have been 42% over the past three years , 24% over the past five years , and 21% over the past ten years .

Back to Top